SCHEMBL16699116

SCHEMBL16699116

CC(C)(C)NC(=O)c1c(-c2ccc(F)c(Cl)c2)nn2c1CN(C(N)=O)CC2C(C)(C)O

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 17/20 0.56
CSNK1D P48730 14/20 0.53
BTK Q06187 1/20 0.37
RIPK2 O43353 1/20 0.37
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17527272 0.94 CSNK1E (0.60) CSNK1ECSNK1DBTK
SCHEMBL16700523 0.92 CSNK1E (0.47) CSNK1ECSNK1DRIPK2
SCHEMBL16700425 0.88 CSNK1E (0.49) CSNK1ECSNK1DBTKRIPK2
SCHEMBL16700771 0.88 CSNK1E (0.49) CSNK1ECSNK1DBTKRIPK2
SCHEMBL16711462 0.88 CSNK1E (0.67) CSNK1ECSNK1D
SCHEMBL16699780 0.87 CSNK1E (0.49) CSNK1ECSNK1DBTKRIPK2
SCHEMBL16699561 0.87 CSNK1E (0.48) CSNK1ECSNK1DBTKRIPK2
SCHEMBL16699919 0.86 CSNK1E (0.56) CSNK1ECSNK1DBTK
SCHEMBL16700267 0.85 CSNK1E (0.47) CSNK1ECSNK1DBTK
SCHEMBL16700548 0.85 CSNK1E (0.63) CSNK1ECSNK1DBTKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9273058-B2 Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-01 US claimed
EP-3068785-B1 SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-06-26 EP disclosed
US-20160122358-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-05 US disclosed
US-9273058-B2 Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-01 US disclosed
US-20150133428-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122358-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS CSNK1E, CSNK1A1, CSNK1G1 CSNK1E 1/4885CSNK1D 7/4885BTK 1624/4885
US-20150133428-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS CSNK1E, CSNK1A1, CSNK1G1 CSNK1E 1/4885CSNK1D 7/4885BTK 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.